INTRODUCTION {#s1}
============

Folate, also named vitamin B9, is a naturally occurring nutrient and is found in many foods including fruits, vegetables legumes, cereals, and liver. Human can't produce folate *de novo* and need to uptake folate from dietary intake. Evidences implicated deficient folate is related to increased risks of many cancers \[[@R1]\].

Folate plays an important role in the process of DNA synthesis, repair, and methylation, and was hypothesized to decrease risks of gastrointestinal cancers. The main carcinogenesis mechanisms of folate are inducing DNA strand breaks by causing uracil mis-incorporation into DNA and changing levels of DNA methylation \[[@R2]\]. These aberrant changes may result in potential alterations of critical proto-oncogene and tumor suppressor gene expressions \[[@R3]\]. Animal experiments referring mice and dogs suggested that high levels of folate intake affected DNA methylation and eventually decreased the risks of gastric cancer \[[@R4], [@R5]\]. In addition, the polymorphisms of genes in folate metabolizing pathway may modulate the susceptibility of several cancers.

Previous studies have summarized published data and indicated that increased folate intake was associated with the increased risks of prostate \[[@R6]\] and breast \[[@R7]\] cancers, but decreased the risks of colorectal \[[@R8]\] and cervical \[[@R9]\] cancers. Two previous meta-analysis have estimated the associations of folate intakes and risks of esophageal, gastric and pancreatic carcinomas and indicated that increased folate intakes were associated with decreased risks of esophageal and pancreatic cancers \[[@R10], [@R11]\]. However, the results of these studies about the relationship between folate intake and gastric cancer risk remained inconsistent. Larsson et al. indicated that increased folate intake were associated with decreased risks of cardia and non-cardia gastric cancers \[[@R11]\]. Basing on more studies, another systematic review showed no relationship between dietary folate intake and risks of gastric cancers \[[@R10]\]. Therefore, to clarify the associations between folate intake and upper gastrointestinal cancers and evaluate the dose-response relationship between them, we performed an overall meta-analysis based on current observational studies.

RESULTS {#s2}
=======

Summary of studies' characteristics {#s2_1}
-----------------------------------

Total 1284 studies were collected from our initial search including studies about esophageal cancer (n=398), gastric cancer (n=335) and pancreatic cancer (n=551). After duplicates automatically removing with EndNote, total 1154 potential articles were remained. Then, after screening titles and abstracts, 983 irrelevant studies were excluded; the remained 171 records, which investigated the associations between upper gastrointestinal cancers and folate intake, were eligibly evaluated with full text reading. Based on our inclusive criteria mentioned in Materials and Methods, 46 articles were eventually included in our meta-analysis. Among all the selected studies, 19 were conducted in patients of esophageal cancer \[[@R12]-[@R30]\], 21 were in patients of gastric cancer \[[@R12], [@R14], [@R15], [@R22], [@R26], [@R28], [@R31]-[@R45]\] and 12 were in patients of pancreatic cancer \[[@R46]-[@R57]\]. Figure [1](#F1){ref-type="fig"} shows the eligible selecting process. Main characteristics of all include articles were showed in Table [1](#T1){ref-type="table"}.

![Flow chart of the literature search used in this meta-analysis](oncotarget-08-86828-g001){#F1}

###### Characteristics of studies included in the meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies              Country            Study Design   Year         Age         Sex   Sample Size (cases/ controls)   Disease type   Exposure range (μg/day)                      Measurement                 Dose-response
  -------------------- ------------------ -------------- ------------ ----------- ----- ------------------------------- -------------- -------------------------------------------- --------------------------- ---------------
  2014\                USA                Cohort         1995-2004    50-71       M/W   GC: 939/492292\                 GC/EC          566 vs 288                                   FFQ (Supplement and diet)   No
  Xiao                                                                                  EC: 759/492292                                                                                                          

  2014\                China              Case-control   2008-2011    \-          M/W   767/765                         GCA/Non-GCA    \>310 vs \<230                               FFQ (Diet)                  Yes
  Chen                                                                                                                                                                                                          

  2013\                China              Case-control   2008-2012    28-76       M/W   264/535                         Non-GCA        \>310 vs \< 230                              FFQ (Diet)                  Yes
  Gao                                                                                                                                                                                                           

  2011\                Uruguay            Case-control   1996-2004    23-89       M/W   GC: 275/2032\                   GC             275.31 vs 123.83                             FFQ (Diet)                  Yes
  Aune                                                                                  EC: 234/2032                                                                                                            

  2010\                China              Cohort         1996-2006    40-70       M/W   338/136442                      GCA/Non-GCA    \>346.5 vs \<218.7                           FFQ (Diet)                  Yes
  Epplein                                                                                                                                                                                                       

  2009 Pelucchi        Italy              Case-control   1997-2007    22-80       M/W   230/547                         GC             The highest vs the lowest quintile           FFQ (Diet)                  No

  2005 Kim             Korea              Case-control   1997-1998    \-          M/W   136/136                         GCA/Non-GCA    \>354 vs \<234                               FFQ (Diet)                  No

  2003 Nomura          USA                Case-control   1993--1999   \-          M/W   300/446                         GC             \>315 vs \<236                               FFQ (Diet)                  No

  2002 Chen            USA                Case-control   1988-1994    \-          M/W   GC: 154/449\                    GC/EC          The highest vs the lowest quintile           FFQ (Diet)                  No
                                                                                        EC: 124/449                                                                                                             

  2000 Botterweck      Netherlands        Cohort         1986-1992    55-69       M/W   310/120852                      GC             \>384.16 vs \<201.96                         FFQ (Diet)                  Yes

  2006\                Sweden             Cohort         1987-2004    40-76       W     156/61433                       GC             \>260 vs \< 203                              FFQ (Supplement and diet)   No
  Larsson                                                                                                                                                                                                       

  2001\                USA                Case-control   1993-1995    30-79       M/W   GC: 607/687\                    GC/EC          The highest vs the lowest quintile           FFQ (Diet)                  No
  Mayne                                                                                 EC: 488/687                                                                                                             

  2001\                Venezuela          Case-control   1991-1997    \>35        M/W   302/485                         GC             The highest vs the lowest quintile           FFQ (Diet)                  No
  Munoz                                                                                                                                                                                                         

  1999\                Mexico             Case-control   1989-1990    24-88       M/W   220/752                         GC             \>466.26 vs \<257.4                          FFQ (Diet)                  Yes
  Lizbeth                                                                                                                                                                                                       

  1994\                Italy              Case-control   1985-1992    19-74       M/W   723/2024                        GC             \>262 vs \<163                               FFQ (Diet)                  Yes
  Vecchia                                                                                                                                                                                                       

  1997 Harrison        USA                Case-control   1992-1994    \-          M/W   31/132                          GC             The highest vs the lowest quintile           FFQ (Diet)                  No

  2004 Lissowska       Poland             Case-control   1994-1996    \-          M/W   274/463                         GC             The highest vs the lowest quintile           FFQ (Diet)                  No

  2016\                China              Cohort         1985-1991    40-69       M/W   GC: 255/29584\                  GC/ESCC        The highest vs the lowest quintile           serum                       No
  Ren                                                                                   ESCC: 498/29584                                                                                                         

  2015\                China              Case-control   2000         \>20        M/W   GC: 206/415\                    GC/EC          The highest vs the lowest quintile           serum                       No
  Chang                                                                                 EC: 218/415                                                                                                             

  2007\                Europe             Case-control   1992-1998    42.7-71.4   M/W   245/631                         GCA/Non-GCA    The highest vs the lowest quintile           serum                       No
  Vollset                                                                                                                                                                                                       

  2014\                China              Case-control   1998-2006    \-          M/W   149/155                         GC             The highest vs the lowest quintile           serum                       No
  Lee                                                                                                                                                                                                           

  2015\                Europe             Case-control   1992-2000    41-71       M/W   ESCC: 126/255\                  ESCC/EAC       The highest vs the lowest quintile           serum                       No
  Fanidi                                                                                EAC: 26/274                                                                                                             

  2013\                Northern Ireland   Case-control   2002-2005    \<85        M/W   223/256                         EAC            ≥421 vs ≤318                                 FFQ (Supplement and diet)   No
  Sharp                                                                                                                                                                                                         

  2013\                China              Case-control   2010-2012    \-          M/W   126/167                         ESCC           The highest vsthe lowest quintile            serum                       No
  Huang                                                                                                                                                                                                         

  2012\                Italy              Case-control   1991-2009    \-          M/W   505/22828                       EC             ≥312.5 vs ≤257.3                             FFQ (Diet)                  Yes
  Tavani                                                                                                                                                                                                        

  2011\                China              Case-control   2008-2010    \-          M/W   155/310                         ESCC           \>300 vs \<230                               FFQ (Diet)                  Yes
  Zhao                                                                                                                                                                                                          

  2011\                Iran               Case-control   \-           40-75       M/W   47/96                           ESCC           The highest vsthe lowest quintile            FFQ (Diet)                  No
  Jessri                                                                                                                                                                                                        

  2011 I\              Australia          Case-control   2003-2006    18-79       M/W   267/393                         ESCC/EAC       379 vs 196                                   FFQ (Diet)                  Yes
  biebele                                                                                                                                                                                                       

  2006\                Italy              Case-control   1992-1999    \<80        Men   351/875                         ESCC           The highest vs the lowest quintile           FFQ (Diet)                  No
  Galeone                                                                                                                                                                                                       

  2006 De Stefani      Uruguay            Case-control   1996-2004    40-89       M/W   234/1032                        ESCC           The highest vs the lowest quintile           FFQ (Diet)                  No

  2005 Yang            Japan              Case-control   2001-2004    18-80       M/W   165/495                         EC             \>400 vs \<300                               FFQ (Diet)                  Yes

  2002 Bollschweiler   Germany            Case-control   1997-2000    \-          M/W   117/100                         ESCC/EAC       \>164 vs \<100                               EBIS (Diet)                 Yes

  2013 Bao             China              Case-control   2010-2011    \-          M/W   106/106                         ESCC           The highest vs the lowest quintile           serum                       No

  1988 Brown           USA                Case-control   1982-1984    \<79        M     74/157                          EC             The highest vs the lowest quintile           FFQ (Supplement and diet)   No

  2011 Chuang          Europe             Cohort         1994         25-70       M/W   638/520000                      PC             The highest vs the lowest quintile           serum                       No

  2011 Bravi           Italy              Case-control   1991-2008    34-80       M/W   326/652                         PC             The highest vs the lowest quintile           FFQ (Diet)                  No

  2010 Oaks            USA                Cohort         1993-2001    55-74       M/W   266/51988                       PC             The highest vs the lowest quintile           FFQ (Supplement and diet)   No

  2009 Keszei          Netherlands        Cohort         1986-1999    55-69       M/W   363/120852                      PC             \>259.1 vs \<176.3                           FFQ (Diet)                  Yes

  2009 Gong            USA                Case-control   1995-1999    21-85       M/W   532/1701                        PC             ≥738 vs \<280                                FFQ (Supplement and diet)   No

  2007 Schernhammer    USA                Case-control   1989-1990    40-75       M/W   247/740                         PC             The highest vs the lowest quintile           serum                       No

  2006 Larsson         Sweden             Cohort         1987-1990    45-83       W     135/81922                       PC             ≥350 vs \<200                                FFQ (Diet)                  Yes

  2004 Skinner         USA                Cohort         1976-1986    40-75       M/W   187/125480                      PC             ≥500 vs \<300                                FFQ (Supplement and diet)   Yes

  2001 Stolzenberg     Finland            Cohort         1985-1988    50-69       M/W   157/27101                       PC             ≥373 vs \<280                                FFQ (Diet)                  Yes

  1999 Stolzenberg     Finland            Case-control   1985-1988    50-69       M/W   126/247                         PC             The highest vs the lowest quintile           serum                       No

  2016\                China              Cohort         1993-1998    45-74       M/W   271/63257                       PC             207 vs 108                                   FFQ (Diet)                  Yes
  Huang                                                                                                                                                                                                         

  2009\                Canada             Case-control   2003-2007    \<75        M/W   422/312                         PC             Folate supplement vs non-folate supplement   FFQ (Supplement and diet)   No
  Anerson                                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: EBIS, ErnahrungsBeratungs und Informations-System; EC, Esophageal Cancer; EAC, esophageal adenocarcinoma; ESCC, Esophageal squamous cell cancer; FFQ, food frequency questionnaire; GC, Gastric Cancer; GCA, Gastric cardiac adenocarcinoma; PC, Pancreatic Cancer.

Esophageal cancer {#s2_2}
-----------------

Probands of 4 studies were in American participants \[[@R15], [@R26], [@R28], [@R29]\], 5 in Chinese \[[@R12], [@R14], [@R17], [@R19], [@R30]\] and 5 in Europeans \[[@R13], [@R16], [@R18], [@R23], [@R27]\]. In terms of the study design, 2 were cohort studies \[[@R12], [@R15], [@R18]\] and 17 were case-control studies \[[@R13], [@R14], [@R16]-[@R25], [@R58]\]. Seven studies clearly reported patients with Esophageal squamous cell cancer (ESCC) \[[@R12], [@R13], [@R15], [@R17], [@R19]-[@R21], [@R23], [@R24], [@R27], [@R28], [@R30]\] and six studies were about esophageal adenocarcinoma (EAC) \[[@R13], [@R15], [@R16], [@R21], [@R26]-[@R28]\]. Eleven studies investigated dietary folate intake from food \[[@R18]-[@R28]\] and 3 studies further examined dietary folate intake from food and supplement \[[@R15], [@R16], [@R29]\]. Five studies reported detecting folate concentration in serum samples from patients \[[@R12]-[@R14], [@R17], [@R30]\]. Six case-control studies \[[@R18], [@R19], [@R21], [@R22], [@R25], [@R27]\] and 1 cohort study \[[@R15]\] which evaluated the association between dietary folate intake without supplement and risk of esophageal cancer were included in dose-response analysis. Two studies didn't set the lowest dose concentration group as reference group \[[@R15], [@R27]\]. The reference group transformation has been described above.

To assess the relationship between the risk of esophageal cancer and dietary folate intake, total 19 studies including 2036 patients and 7086 controls were collected. The forest plot is shown in Figure [2A](#F2){ref-type="fig"}. Significant heterogeneity (p\<0.001, I^2^ = 73.7%) between these studies suggested that a random effect model was selected. The pooled results showed that dietary folate intake comparing highest levels vs. lowest levels was associated with the decreased risk of esophageal cancer (odds ratio (OR) = 0.545, 95% confidence interval (CI) = 0.432-0.658, Table [2](#T2){ref-type="table"}).

![Forest plots of the association between dietary folate intake and risk of esophageal cancer (A), gastric cancer (B) and pancreatic cancer (C)](oncotarget-08-86828-g002){#F2}

###### Results including overall and subgroup analysis of pooled OR, 95%CI, heterogeneity test and publication bias

  Overall and subgroup analysis   Numbers of studies   Pooled OR   95%CI         Heterogeneity Test   Publication Bias (*P*)                  
  ------------------------------- -------------------- ----------- ------------- -------------------- ------------------------ ------ ------- -------
  **Esophageal cancer**                                                                                                                       
  Total                           20                   0.545       0.432-0.658   87.57                \<0.001                  73.7   0.027   0.023
  **Study design**                                                                                                                            
  Cohort                          2                    0.821       0.569-1.073   4.11                 0.128                    51.4   0.466   0.602
  Case-control                    17                   0.496       0.386-0.606   59.90                \<0.001                  68.3   0.080   0.130
  **Histological type**                                                                                                                       
  ESCC                            7                    0.551       0.370-0.731   51.39                \<0.001                  80.5   0.152   0.091
  EAC                             6                    0.561       0.373-0.749   20.15                0.003                    70.2   0.141   0.142
  **Country**                                                                                                                                 
  USA                             4                    0.573       0.474-0.673   5.70                 0.336                    12.3   0.573   0.708
  China                           5                    0.596       0.255-0.938   36.06                \<0.001                  91.7   0.174   0.125
  Europe                          5                    0.443       0.238-0.647   15.91                0.014                    62.3   0.348   0.125
  Others                          6                    0.770       0.450-1.310   15.35                0.009                    67.4   0.188   0.043
  **Measurement**                                                                                                                             
   Diet                           11                   0.547       0.426-0.667   33.92                0.001                    61.7   0.01    0.01
   Supplement and diet            3                    0.692       0.530-0.853   1.99                 0.574                    0      0.412   0.327
   Serum                          5                    0.708       0.329-1.088   40.56                \<0.001                  87.7   0.458   0.117
  **Gastric cancer**                                                                                                                          
   Total                          21                   0.762       0.648-0.876   77.08                \<0.001                  67.6   0.808   0.270
  **Study design**                                                                                                                            
   Cohort                         5                    0.967       0.801-1.134   4.46                 0.615                    0      0.548   0.652
   Case-control                   16                   0.696       0.563-0.829   65.83                \<0.001                  72.7   0.960   0.248
  **Histological type**                                                                                                                       
   GCA                            3                    0.729       0.531-0.927   1.14                 0.566                    0      0.590   0.117
   Non-GCA                        4                    0.681       0.549-0.813   4.09                 0.252                    26.6   0.761   1
   Other GC                       17                   0.796       0.646-0.947   70.20                \<0.001                  74.4   0.725   0.278
  **Country**                                                                                                                                 
   USA                            5                    0.627       0.539-0.715   11.11                0.134                    37.0   0.510   0.621
   Europe                         5                    0.889       0.562-1.215   9.70                 0.084                    48.5   0.226   0.573
   China                          7                    0.864       0.579-1.149   22.58                0.002                    69.0   0.236   0.322
   Others                         4                    0.859       0.552-1.166   9.76                 0.021                    69.3   0.885   1
  **Measurement**                                                                                                                             
   Diet                           18                   0.714       0.591-0.836   60.25                \<0.001                  71.8   0.216   0.622
   Supplement and diet            2                    0.884       0.654-1.115   0.76                 0.683                    0      0.015   0.043
   Serum                          4                    1.217       0.475-1.960   9.65                 0.047                    58.6   0.849   0.624
  **Sex**                                                                                                                                     
   Women                          3                    0.857       0.405-1.309   6.01                 0.050                    66.7   0.416   0.602
   Men                            2                    0.599       0.088-1.109   2.98                 0.085                    66.4   0.656   0.251
  **Pancreatic cancer**                                                                                                                       
   Total                          12                   0.731       0.555-0.907   35.44                \<0.001                  69.0   0.089   0.054
  **Study design**                                                                                                                            
   Cohort                         7                    0.800       0.512-1.089   28.43                \<0.001                  78.9   0.029   0.015
   Case-control                   5                    0.589       0.456-0.722   6.01                 0.198                    33.5   0.829   1
  **Country**                                                                                                                                 
   USA                            4                    0.885       0.565-1.206   9.08                 0.028                    67.0   0.604   0.497
   Europe                         5                    0.457       0.326-0.588   5.75                 0.218                    30.5   0.069   0.050
   Others                         3                    1.006       0.759-1.252   2.94                 0.230                    32.0   0.709   0.602
  **Measurement**                                                                                                                             
   Diet                           8                    0.669       0.450-0.888   21.93                0.001                    72.6   0.156   0.099
   Supplement and diet            5                    0.756       0.559-0.952   6.65                 0.156                    39.8   0.831   0.49
   Serum                          3                    0.763       0.338-1.189   5.84                 0.054                    65.7   0.068   0.117
  **Sex**                                                                                                                                     
   Men                            5                    0.856       0.709-1.003   1.97                 0.742                    0      0.836   1
   Women                          5                    0.716       0.557-0.874   2.89                 0.577                    0      0.563   0.624

Abbreviations: EC: Esophageal Cancer; EAC: esophageal adenocarcinoma; ESCC: Esophageal squamous cell cancer; GC: Gastric Cancer; GCA: Gastric cardiac adenocarcinoma; OR: odds ration; CI: confidence interval.

Table [2](#T2){ref-type="table"} showed the results of specific subgroup analysis based on study designs, countries, histological type and folate intake measurement. All these results were similar in subgroup analysis suggested that folate intake were comprehensive associated with reduced risk of esophageal cancer.

As shown in Figure [3A](#F3){ref-type="fig"}, the linearity test of dose-response analysis suggested that with increased 100 μg/day folate intake from diet, the risk of esophageal cancer decreased 9% degree (OR=0.91, 95%CI=0.88-0.94). The non-linearity test (*p*\<0.001) indicated that the lowest risk of esophageal cancer was at the dose of 405 μg/day (OR=0.69, 95%CI=0.57-0.83). After the dose of folate intake \> 405 μg/day, the risk of esophageal cancer would increase after the fall.

![Linearity and non-linearity relationships between dietary folate intake and risk of esophageal cancer (A), gastric cancer (B) and pancreatic cancer (C)](oncotarget-08-86828-g003){#F3}

Gastric cancer {#s2_3}
--------------

Totally 5 studies were about American participants \[[@R15], [@R26], [@R28], [@R37], [@R42], [@R43]\], 5 were about European participants \[[@R35], [@R39], [@R42], [@R44], [@R58]\] and 7 were about Chinese participants \[[@R12], [@R14], [@R22], [@R31], [@R32], [@R34], [@R45]\]. In terms of the study design, 5 were cohort studies \[[@R12], [@R15], [@R34], [@R38], [@R39]\] and 16 were case-control studies \[[@R14], [@R22], [@R26], [@R28], [@R31], [@R32], [@R35]-[@R37], [@R40]-[@R45], [@R58]\]. Three studies clearly reported patients with gastric cardiac adenocarcinoma (GAC) \[[@R15], [@R28], [@R44]\] and 4 studies were about Non-GAC \[[@R15], [@R28], [@R32], [@R44]\]. Eighteen studies investigated dietary folate intake from food \[[@R22], [@R26], [@R28], [@R31], [@R32], [@R34]-[@R38], [@R40]-[@R43], [@R58]\] and 2 studies further examined dietary folate intake from food and supplement \[[@R15], [@R39]\]. Four studies reported detecting folate concentration in serum samples from patients \[[@R12], [@R14], [@R44], [@R45]\]. Two studies have respectively investigated the association between folate intake and risk of gastric cancer by sex \[[@R34], [@R37]\]. One study only included women participant \[[@R39]\]. Five case-control studies \[[@R22], [@R31], [@R32], [@R41], [@R42]\] and four cohort studies \[[@R15], [@R34], [@R38], [@R39]\] which evaluated the associations between dietary folate intake and risks of gastric cancer were included in dose-response analysis. One study didn't set the lowest dose concentration group as reference group \[[@R15]\]. The reference group transformation has been described above.

As shown in Figure [2B](#F2){ref-type="fig"}, 5 cohort studies and 16 case-control studies were collected to analyze the association between dietary folate intake and risk of gastric cancer. The comprehensive pooled relative risk (RR) indicated a significant association between increased folate intake and decreased risk of gastric cancer (OR=0.762, 95%CI=0.648-0.876, Table [2](#T2){ref-type="table"}). There was a significant heterogeneity (*p*\<0.001, I^2^=67.6%) which suggested a further subgroup analysis.

Table [2](#T2){ref-type="table"} showed the results of specific subgroup analysis based on study designs, countries, histological type, folate intake measurement and sex. When stratified by cohort studies, 5 studies were included and indicated no statistically significant association existing between dietary folate intake and risk of gastric cancer (OR=0.967, 95%CI=0.801-1.134). The pooled OR of case-control studies suggested a high dietary folate intake was associated with a statistically significant decreased risk of gastric cancer (OR=0.696, 95%CI=0.563-0.829). Subgroup analysis by country demonstrated that there was a significant association between increased folate intake with decreased risk of gastric cancer in Americans (OR=0.627, 95%CI=0.539-0.715) and no associations in Chinese (OR=0.864, 95%CI=0.579-1.149), Europeans (OR=0.889, 95%CI=0.562-1.215) and other countries (OR=0.859, 95%CI=0.552-1.166). Subgroup analysis by histological type indicated that increased dietary folate intake were significantly associated both with Gastric cardiac adenocarcinoma (GCA) (OR=0.729, 95%CI=0.531-0.927) and non-GCA (OR=0.681, 95%CI=0.549-0.813). Subgroup analysis by measurement suggested that high dietary folate intake from diet was associated with a statistically significant decreased risk of gastric cancer (OR=0.714, 95%CI=0.591-0.836). However, there was no association between high dietary folate intake from diet and supplement and risk of gastric cancer (OR=0.884, 95%CI=0.654-1.115). Detecting folate levels in serum suggested that there was no association between folate intake and risk of gastric cancer (OR=1.217, 95%CI=0.475-1.960). Increased folate intake was associated with decreased risk of gastric cancer in men (OR=0.599, 95%CI=0.088-1.109, but not in women (OR=0.857, 95%CI=0.405-1.309).

As shown in Figure [3B](#F3){ref-type="fig"}, non-linearity (p=0.20) dose-response analysis indicated no relationship between folate intake from diet and risk of gastric cancer. However, a linearity relationship (p=0.03) was found and suggested that 1.5% decrease of gastric cancer for each 100 μg/day increase of dietary folate intake (OR=0.985, 95%CI=0.972-0.998).

Pancreatic cancer {#s2_4}
-----------------

Probands of 4 studies were in American participants \[[@R48], [@R50], [@R51], [@R53]\], 5 in Europeans \[[@R46], [@R47], [@R52], [@R54], [@R55]\] and 5 in other countries. In terms of the study design, 7 were cohort studies \[[@R46], [@R48], [@R49], [@R52]-[@R54], [@R56]\] and 5 were case-control studies \[[@R47], [@R50], [@R51], [@R55], [@R57]\]. Eight studies investigated dietary folate intake from food \[[@R47]-[@R50], [@R52], [@R56]\] and 5 studies further examined dietary folate intake from food and supplement \[[@R48], [@R50], [@R53], [@R54], [@R57]\]. Three studies reported detecting folate concentration in serum samples from patients \[[@R46], [@R51], [@R55]\]. Five studies have respectively investigated the association between folate intake and risk of pancreatic cancer by sex \[[@R46]-[@R48], [@R53], [@R56]\]. Total 7 studies were included in dose-response analysis \[[@R48]-[@R50], [@R52]-[@R54], [@R56]\].

As shown in Figure [2C](#F2){ref-type="fig"}, 7 cohort studies and 5 case-control studies were collected to analyze the association between dietary folate intake and risk of pancreatic cancer. The comprehensive pooled RR indicated a significant association between increased folate intake and decreased risk of pancreatic cancer (OR=0.731, 95%CI=0.555-0.907, Table [2](#T2){ref-type="table"}). There was a significant heterogeneity (p\<0.001, I^2^=69.0%) which suggested a further subgroup analysis.

Table [2](#T2){ref-type="table"} showed the results of specific subgroup analysis based on study designs, countries, folate intake measurement and sex. The pooled result of cohort studies suggested a weak association existing between dietary folate intake comparing highest levels vs. lowest levels and decreased risk of pancreatic cancer (OR = 0.800, 95%CI = 0.512-1.089). The pooled OR of case-control studies suggested a high dietary folate intake was associated with a statistically significant decreased risk of pancreatic cancer (OR=0.589, 95%CI=0.456-0.722). Subgroup analysis by country demonstrated that there was a significant association between increased folate intake with decreased risk of pancreatic cancer in Europeans (OR=0.457, 95%CI=0.326-0.588) and no associations in Americans (OR=0.885, 95%CI=0.565-1.206) and other countries (OR=1.006, 95%CI=0.759-1.252). Evaluating the association between risks of pancreatic cancer and increased folate intake from diet with (OR=0.756, 95%CI=0.559-0.952) or without supplement (OR=0.669, 95%CI=0.450-0.888) suggested that a superfluous folate supplement is not needed. Detecting folate levels in serum suggested that there was a statistically significant association between folate intake and risk of pancreatic cancer (OR=0.763, 95%CI=0.338-1.189). Increased folate intake was associated with decreased risk of pancreatic cancer in women (OR=0.716, 95%CI=0.557-0.874), but not in men (OR=0.856, 95%CI=0.709-1.003).

As shown in Figure [3C](#F3){ref-type="fig"}, the linearity test of dose-response analysis suggested that with increased 100 μg/day folate intake from diet, the risk of pancreatic cancer decreased 6% degree (OR=0.94, 95%CI=0.92-0.97,). The non-linearity test (*p*\<0.001) also indicated that the risk of pancreatic cancer decreased with folate intake increasing.

Sensitivity analysis and publication bias {#s2_5}
-----------------------------------------

One included study of this meta-analysis was omitted each time to evaluate the stability of pooled results. The results remained similar when any result was removed from the pooled results in this meta-analysis. Begg's test and Egger's test were used to evaluate the publication bias, the results were summarized in Table [2](#T2){ref-type="table"}. There were significant publication biases in the results which evaluate the associations between folate intake and esophageal cancer (Egger's test: p=0.027; Begg's test: p=0.023); esophageal cancer in diet (Egger's test: p=0.01; Begg's test: p=0.01); pancreatic cancer in cohort subgroup analysis (Egger's test: p=0.029; Begg's test: p=0.015) and gastric cancer in supplement and diet subgroup analysis (Egger's test: p=0.015; Begg's test: p=0.043). The trim-and-fill method was used to re-calculate the publication bias. All the new results remained similar to the original results. These results were considered as steady.

DISCUSSION {#s3}
==========

Folate is a water-soluble B vitamin and is found in many foods including fruits, vegetables legumes, cereals, and liver. Human can't produce folate *de novo* and need to uptake folate from dietary intake \[[@R1], [@R59]\]. Folate plays an important role in the process of DNA synthesis, repair, and methylation, and was hypothesized to decrease risks of gastrointestinal cancers. Two main mechanisms of folate deficiency leads to carcinogenesis: (1) by leading complete convention of dUMP to dTMP, which makes mis-incorporation of uracil into DNA and induces breaks and mutations of chromosome; and/or (2) inducing alternations in expression of critical proto-oncogenes and tumor suppressor genes by causing aberrant methylated level of DNA \[[@R2], [@R3]\]. In addition, the polymorphisms of 5,10-methylenetetrahydrofolate reductase, a critical junction protein in folate metabolizing pathway by leading folate metabolites to DNA methylation pathway and away from the DNA synthesis pathway, can regulate the susceptibilities of several cancers \[[@R60]-[@R62]\].

Our meta-analysis found that increased folate intake was associated with reduced risks of upper gastrointestinal cancers including esophageal, gastric and pancreatic cancers. The dose-response further certified their relationship. Subgroup analysis indicated that the comprehensive inverse associations between dietary folate intake and esophageal cancer. Our data suggested different relationships between dietary folate intake and cancer risks in country, study design, disease type, measurement and sex subgroup analysis of gastric and pancreatic cancers.

The results of this meta-analysis showed that increased dietary folate intake significant decreased risk of esophageal cancer. These results are similar to previous study \[[@R10], [@R11], [@R63]\]. In the subgroup analysis based on country, histological type, study design and dietary measurement, our results suggested an inverse association between dietary folate intake and risks of esophageal cancer in all subgroups. Interesting, we observed a higher OR which suggested a weaker link between folate intake and esophageal cancer in supplement and diet subgroup than in diet subgroup. These results suggested an extra folate supplement is not needed in diet for preventing esophageal cancer. The results of dose-response analysis also indicated that with the folate intake \> 450 μg/day, the risk of esophageal cancer would increase weakly comparing with the lowest OR, which suggested that a redundant and supplementary folate is not necessary. Zhang et al. found that the risk ration of breast cancer decreased when the dose of folate was low. However, with the folate dose increasing, a positive association was found between folate intake and breast cancer risk \[[@R7]\].

Different from previous studies \[[@R10], [@R11]\], our results showed a significant association between increased dietary folate intake and reduced gastric cancer risk. Although non-linearity model of dose-response analysis suggested no statistically significant association between folate intake and risk of gastric cancer, linearity model indicated a different result (p=0.03) which certificated our comprehensive pooled OR. Meta-analysis of genetic polymorphisms demonstrated that folate deficiency was associated with increased risk of gastric cancer \[[@R11], [@R64], [@R65]\]. Folate supplement can reverse methylation deficiency, stop global hypomethylation and prevent gastric carcinogenesis in hypergastrinemic transgenic mice \[[@R5]\]. Subgroup analysis indicated an inverse association between dietary folate intake and gastric cancer risk in case-control studies, but no association in cohort studies. A possible reason is that only 5 cohort studies were included in this analysis. Small number of studies and effects of multiple factors may affect recall bias and selection bias and restrict the precision of the last results. Similar to previous studies \[[@R11]\], our data showed a significant inverse association between folate intake and GCA or non-GCA, and a weak inverse link between folate intake and other gastric cancer. These results suggested that dietary folate intake plays different roles in different gastric cancers. In the subgroup analysis based on country, we observed an inverse association between folate intake and gastric cancer only in USA, but not in other countries. In addition, in the subgroup analysis based on measurement, our results showed an inverse association between folate intake coming from diet and risk of gastric cancer. However, no association between folate intake coming from diet and supplement and risk of gastric cancer was found. These results also suggested that an extra folate supplement is not needed in diet for preventing gastric cancer. And the excessive intake of folate may be a risk for gastric cancer since the highest values of 95%CI \> 1.00. Different from previous estimate, serum evaluating suggested an increased risk of gastric cancer with high serum concentration. One possible explanation is that since the number of included studies about serum detection of folate and gastric cancer risk is too small, which provide insufficient statistical power to evaluate the risk. Animal experiments suggested a dual role of folate in cancer carcinogenesis: prevention or promotion, depending on the stage of cell transformation at the time of intervention and the dose of folate supplement \[[@R66], [@R67]\]. Significant decreased risks of gastric cancers were observed both in men and women with folate intake increased.

Results of previous meta-analysis about folate intake and pancreatic cancer risk were inconsistent. Bao et al. found folate intake was not associated with overall risk of pancreatic cancer using only prospective cohort studies \[[@R68]\]. However, other studies considered increased folate intake was associated with decreased pancreatic cancer risk \[[@R11], [@R69]\]. Our comprehensive meta-analysis found an inverse association between dietary folate intake and pancreatic cancer risk. Dose-response analysis indicated that a 100 μg/day increment in dietary folate intake was associated with a 6% risk decreasing for pancreatic cancer. Results of subgroup analysis based on country showed an inverse association between folate intake and pancreatic cancer risk in European. However, this association was not found in American and other countries. These results suggested that geographic variation or dietary habit may play an important role in the association. Subgroup analysis by sex indicated that women had higher pancreatic risk with low folate intake when compared with men. Similar to esophageal and gastric cancers, our data showed that an extra folate supplement is not needed in diet for preventing pancreatic cancer.

There are several limitations to current meta-analysis. First, the included studies about esophageal, gastric and pancreatic cancer have few cohort studies which may make influence on the actual result. Since, dose-response analysis didn't separate cohort and case-control studies. Second, subgroup analysis based on measurement only included diet, diet and supplement and serum. Total folate intake and other folate intake measurements were not evaluated for lack of related studies. Third, significant heterogeneity were detected between the studies included in quantitative synthesis. Through further subgroup analysis, we still can't find all the origin of heterogeneity. Forth, this meta-analysis used pooled results for lacking of individual data, which prevents us from finishing a more precise analysis. Last, some subgroup analysis which included small number of studies may not represent objective and exact results. Hence, our results should be treated as exploratory and with caution.

In conclusion, results of current meta-analysis indicated that higher level of dietary folate intake could help for preventing upper gastrointestinal cancers including esophageal, gastric and pancreatic cancers. Dose-response analysis indicated that with 100μg/day increment in dietary folate intake, the risk of esophageal, gastric and pancreatic cancers would decrease by 9%, 1.5% and 6%, respectively. In addition, our analysis indicated that more well-designed studies about associations between esophageal, gastric and pancreatic cancers and folate intake are necessary for further accurately evaluating subgroup analysis based on country, measurement, histological type and sex.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

A systematically search was performed up to May 2^th^, 2017 by two reviewers (H. Z. and Y. Z.) within Pubmed, MEDLINE AND EMBASE, using the terms "folate, folic acid or vitamin B9", "esophageal, oesophagus, gastric, stomach, or pancreatic" and "cancer, neoplasm or carcinoma". In addition, we reviewed the reference lists from original reports and manually selected for other available publications. No language restrictions were imposed in the searching process.

Study selection {#s4_2}
---------------

The studies were included with the following inclusion criteria: (i) the experimental design was a case-control or cohort study; (ii) studies reported the associations of esophageal, gastric, or pancreatic cancer risk with dietary folate intake from diet, dietary folate intake from diet and supplement and serum levels of folate; (iii) RR, hazard ration (HR) or OR with 95% CI was reported to estimate the relative risk of the highest folate intake vs. lowest folate intake; (iv) patient with disease was identified by histological diagnosis; (v) for dose-response analysis, the number of cases and participants and eligible dose concentration must be provided. The selected studies were only limited in using dietary folate intake as only measurement standard. The most recent study was included for duplicate publications.

Data extraction {#s4_3}
---------------

The following information was selected independently by two authors (H. Z. and Y. Z.) according to the criteria listed previously: the first author's name, publication year, country, study design, total sample size, sex, number of cases, number of controls, lowest folate level, highest folate level, difference between highest and lowest folate levels, measurement, range of exposure, histological type (ESCC, EAC, gastric cardiac adenocarcinoma (GAC); non-GAC), risk estimates and 95%CI for evaluating the highest folate levels vs. lowest folate levels. Adjusted rations were chosen in preference to the rations with the highest number of adjusted variables. For the studies which the reference groups were not the lowest dose concentration, the EXCEL macro document (RRest9) was used for the reference group transforming and data re-calculating according to the instructions \[[@R70]\]. All controversial questions were resolved by asking a third author.

Statistical analysis {#s4_4}
--------------------

The association of folate intake with esophageal, gastric and pancreatic cancers were examined by the pooled risk estimates (RR or OR) with 95%CI. The heterogeneity test was detected with I^2^ statistic. Cut-off points of I^2^ value for low, moderate and high degrees of heterogeneity were 25%, 50% and 75%, respectively. A fixed effect model was chosen when heterogeneity was negligible, otherwise, the random effects model was chosen \[[@R71]\]. Sensitivity analysis was investigated to assess robust of pooled results by omitting one study each time. The publication bias was determined by the Begg rank correlation test and Egger's linear regression test \[[@R72]\]. P\<0.05 was considered statistically significant, and all p-values were two-sided. The trim-and-fill method was used to re-calculate the publication bias when the P values of Begg test or Egger test \>0.05. The new pooled results (RR or OR) were compared with the original results. The results were considered as steady if the new pooled results are similar to the original results. At last, we conducted a dose-response meta-analysis using the correlated natural logs of the RRs or ORs with their standard error (SE) across all folate intake categories \[[@R73]\]. To derive the dose-response curve, restricted cubic splines with four knots at the 5%, 35%, 65% and 95% percentiles of the distribution were used to assess for potential curvilinear relations. All data in this meta-analysis were performed using Stata 12.0 (StataCorp LP, College Station, TX, USA).
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CI

:   confidence interval

ESCC

:   esophageal squamous cell cancer

EAC

:   esophageal adenocarcinoma

EBIS

:   ErnahrungsBeratungs und Informations-System

FFQ

:   food frequency questionnaire

GAC

:   gastric cardiac adenocarcinoma

HR

:   hazard ration

OR

:   odds ratio

PC

:   Pancreatic Cancer

RR

:   relative risk
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